Damon Race: Can Gene Therapy Deliver Durable Expression Over Time?
Damon Race, President and CEO of GeneVentiv Therapeutics, Inc., shared on LinkedIn:
”The first generation of hemophilia A gene therapies changed the field in an important way.
The question is no longer simply whether gene therapy can reduce bleeding.
The question is whether gene therapy can deliver durable expression over time.
Patients remain highly interested in gene therapy, but long-term durability has become central to adoption decisions for both patients and providers.
At GeneVentiv, this understanding shaped the design and program development of GENV-HEM (AAV8.FVa), which leverages native hepatic biology associated with Factor V expression.
Importantly, our vision for the future of hemophilia A gene therapy includes inhibitor patients.
Patient decisions to adopt gene therapy will ultimately be made not just by efficacy, but by durability.”
Stay updated with Hemostasis Today.
-
Sep 29, 2026, 13:12Wolfgang Miesbach: Teclistamab Targets the Source of Pathogenic Autoantibodies
-
Sep 29, 2026, 12:37Dan Milikovsky: Uncovering Cerebrovascular Injury in Sickle Cell Disease
-
Sep 29, 2026, 12:02Hajra Malik: Bridging Language Gaps in Hematology With AI
-
Sep 29, 2026, 11:57Joan Montaner: Can Blood Test Identify Intracerebral Hemorrhage Within Minutes?
-
Sep 29, 2026, 11:43From Years Without Answers to Life With Hemophilia Care – WFH
-
Sep 29, 2026, 11:32Sara Al Dallal: Transforming Hemophilia Care Across the Gulf
-
Sep 29, 2026, 11:21Richard Davis: Rapid Rescue in Massive Pulmonary Embolism
-
Sep 29, 2026, 11:14Nissan Brown: Every Step Counts for the Hemophilia Community
-
Sep 29, 2026, 11:03Zain Khalpey: SINGLE AF Adds New Evidence to the Anticoagulation Debate